By associating genetic modifiers of HD outcomes to individual-specific somatic expansion scores, these data support somatic expansion as a factor in HD pathogenesis and further highlight FAN1, MSH3, MLH3 and MLH1 and other components of the expansion pathway and/or the sequence integrity of the CAG repeat tract as potential therapeutic targets in this disorder. Here, MLH3 is linked to Huntington disease.